

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

THIS PAGE BLANK (USPTO)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | | | | | | | | | | | | | | | | |
|---|------------------------------|--|------------|---------------------------|----|------------|---------------------------|----|------------|---------------------------|----|-----------|--------------------------|----|-----------|------------------------------|----|
| (51) International Patent Classification ⁶ : A61K 31/35 | | (11) International Publication Number: WO 98/14189 | | | | | | | | | | | | | | | |
| | | (43) International Publication Date: 9 April 1998 (09.04.98) | | | | | | | | | | | | | | | |
| <p>(21) International Application Number: PCT/GB97/02664</p> <p>(22) International Filing Date: 29 September 1997 (29.09.97)</p> <p>(30) Priority Data:</p> <table> <tr> <td>60/027,223</td> <td>1 October 1996 (01.10.96)</td> <td>US</td> </tr> <tr> <td>60/027,222</td> <td>1 October 1996 (01.10.96)</td> <td>US</td> </tr> <tr> <td>60/027,224</td> <td>1 October 1996 (01.10.96)</td> <td>US</td> </tr> <tr> <td>9716805.8</td> <td>9 August 1997 (09.08.97)</td> <td>GB</td> </tr> <tr> <td>9719203.3</td> <td>11 September 1997 (11.09.97)</td> <td>GB</td> </tr> </table> <p>(71) Applicants (for all designated States except US): SMITHKLINE BEECHAM CORPORATION [US/US]; One Franklin Plaza, Philadelphia, PA 19103 (US). SMITHKLINE BEECHAM PLC [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (for US only): HENKEL, Timothy, John [US/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HATTON, Anthony, Guy [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). TALLON, Teresita, Regina, Geradine [IE/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Sci-</p> | | | 60/027,223 | 1 October 1996 (01.10.96) | US | 60/027,222 | 1 October 1996 (01.10.96) | US | 60/027,224 | 1 October 1996 (01.10.96) | US | 9716805.8 | 9 August 1997 (09.08.97) | GB | 9719203.3 | 11 September 1997 (11.09.97) | GB |
| 60/027,223 | 1 October 1996 (01.10.96) | US | | | | | | | | | | | | | | | |
| 60/027,222 | 1 October 1996 (01.10.96) | US | | | | | | | | | | | | | | | |
| 60/027,224 | 1 October 1996 (01.10.96) | US | | | | | | | | | | | | | | | |
| 9716805.8 | 9 August 1997 (09.08.97) | GB | | | | | | | | | | | | | | | |
| 9719203.3 | 11 September 1997 (11.09.97) | GB | | | | | | | | | | | | | | | |
| <p>ence Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). SCOTT, Hugh [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). HILTON, Jane, Elizabeth [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB).</p> <p>(74) Agent: CONNELL, Anthony, Christopher; SmithKline Beecham plc, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).</p> <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> | | | | | | | | | | | | | | | | | |
| <p>(54) Title: USE OF MUPIROCIN FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH COLONISATION OF THE NASOPHARYNX BY PATHOGENIC ORGANISMS</p> <p>(57) Abstract</p> <p>Mupirocin or a salt or ester thereof may be used to treat recurrent sinusitis and recurrent otitis, in particular with novel spray or cream formulations adapted for administration to the nasopharynx.</p> | | | | | | | | | | | | | | | | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | | | |
|-----------|--------------------------|-----------|---------------------------------------|-----------|---|-----------|--------------------------|
| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| AZ | Azerbaijan | GB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinea | MK | The former Yugoslav Republic of Macedonia | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | ML | Mali | TR | Turkey |
| BG | Bulgaria | HU | Hungary | MN | Mongolia | TT | Trinidad and Tobago |
| BJ | Benin | IE | Ireland | MR | Mauritania | UA | Ukraine |
| BR | Brazil | IL | Israel | MW | Malawi | UG | Uganda |
| BY | Belarus | IS | Iceland | MX | Mexico | US | United States of America |
| CA | Canada | IT | Italy | NE | Niger | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NL | Netherlands | VN | Viet Nam |
| CG | Congo | KE | Kenya | NO | Norway | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NZ | New Zealand | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's Republic of Korea | PL | Poland | | |
| CM | Cameroon | KR | Republic of Korea | PT | Portugal | | |
| CN | China | KZ | Kazakhstan | RO | Romania | | |
| CU | Cuba | LC | Saint Lucia | RU | Russian Federation | | |
| CZ | Czech Republic | LI | Liechtenstein | SD | Sudan | | |
| DE | Germany | LK | Sri Lanka | SE | Sweden | | |
| DK | Denmark | LR | Liberia | SG | Singapore | | |

USE OF MUPIROCIN FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF BACTERIAL INFECTIONS ASSOCIATED WITH COLONISATION OF THE NASOPHARYNX BY PATHOGENIC ORGANISMS

The present invention relates to the use of mupirocin or a salt or ester thereof in treating certain bacterial infections, in particular recurrent otitis media and recurrent sinusitis, and
5 to formulations for use in such treatment.

Mupirocin, formerly known as pseudomonic acid, is a therapeutically useful compound which exhibits good antibacterial activity, mainly against Gram-positive bacteria, but also against some Gram-negative bacteria such as *Haemophilus influenzae* and *Moraxella catarrhalis*. It acts as a selective reversible inhibitor of bacterial iso-leucyl t-RNA synthetase, thereby inhibiting bacterial protein synthesis (see Merck Index, 11th edn, 10 1989, 993 and references therein). The compound has an ester moiety which is susceptible to metabolism, effectively excluding the systemic use of the compound. It is however clinically effective as a topical agent.
15

Topical antibacterial compositions comprising mupirocin are marketed by SmithKline Beecham under the trade names Bactroban Ointment and Bactroban Nasal. The first product is an ointment comprising a water soluble polyethylene glycol base (see also EP 0 095 897-A, Beecham Group) whilst the second product comprises the calcium salt of mupirocin in a white soft paraffin based ointment containing a glycerin ester (see also EP 0 167 856-A, Beecham Group). More recently, topical creams comprising mupirocin or a salt thereof have been described (PCT/US94/12026, SmithKline Beecham). The formulation comprising the calcium salt of mupirocin in a white soft paraffin based ointment containing a glycerin ester (Bactroban Nasal) is particularly useful when applied to the anterior nares for the prophylactic eradication of the nasal carriage of *Staph aureus*.
20 More recently, it has been found that the impact of such application is limited to the anterior nares. There is no significant reduction in the colonisation (by *H. influenzae*, *S. pneumoniae* and *M. catarrhalis*) of the nasopharynx (unpublished).
25

A further potential therapeutic use of mupirocin has been described by Nsouli *et al* (poster presented at the Annual Meeting of the American College of Allergy, Asthma and Immunology, 10-15 November 1995 and published in Annals of Allergy, Asthma and Immunology, January 1996, 76(1), 117). A spray formulation comprising Bactroban Ointment diluted in a 1:9 ratio with a saline solution (Ocean, Fleming & Co) was shown
30 to be effective in reducing the incidence of recurrent paranasal sinusitis when administered twice daily (two 'puffs' of spray, estimated to be about 150-200µl) over a seven month period. It is believed that efficacy of the mupirocin/saline combination is
35

the result of eradication of nasal carriage of pathogenic bacteria associated with the recurrent episodes as the formulation would have no direct access to the sinus mucosa due to a small ostium which separates the nasopharynx from the maxillary sinuses. This dosage regimen may however not be ideal as there is concern that the use of a relatively low dosage over a prolonged period may encourage the development of mupirocin resistant bacteria. Furthermore, there may also be concerns about the desirability of the long term usage of aqueous solutions of mupirocin, given the known susceptibility of mupirocin to degradation in such an environment. There still remains the problem of providing a method of treatment for recurrent sinusitis which is devoid of the concerns mentioned above. In addition, there was no suggestion of other diseases which might be susceptible to similar treatment.

Otitis media is a disease state commonly seen in infants and young children. The acute condition is normally successfully treated with a systemic antibacterial agent such as amoxycillin, optionally in combination with potassium clavulanate. *H. influenzae*, *S. pneumoniae* and *M. catarrhalis* are generally considered to be the most common bacterial pathogens. There however remains the problem of treating the recurrent painful episodes.

Accordingly, in a first aspect, the present invention provides for the use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for the prophylactic treatment of bacterial infection associated with colonisation of the nasopharynx by pathogenic organisms, and in which the medicament is adapted for administration to, and residence within, the nasopharynx; excluding the use of a 0.2% saline solution of mupirocin for treating recurrent sinusitis, administered at a dosage of less than 1mg a day, twice daily on a continuing basis.

Typical bacterial infections include recurrent otitis media and recurrent sinusitis.

Accordingly, in a further aspect, the present invention provides for the use of the use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for the prophylactic treatment of recurrent otitis media.

In addition, the present invention also provides for the use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for the prophylactic treatment of recurrent sinusitis.

As used herein, the term 'prophylactic treatment' includes not only complete elimination of the bacterial infection, for instance recurrent otitis media or recurrent sinusitis, but also a partial elimination of thereof, that is a reduction in the number of acute episodes.

5 It is believed that the successful treatment of bacterial infections, such as recurrent otitis media and recurrent sinusitis, is associated with the elimination or reduction of nasal carriage of pathogenic bacteria such as *S. aureus*, *H. influenzae*, *S. pneumonia* and *M. catarrhalis*, in particular colonisation of the nasopharynx by such organisms.

10 Accordingly, in a further aspect, the present invention provides for the use of mupirocin or a pharmaceutically acceptable ester or salt in the manufacture of a medicament for reducing or eliminating the nasal carriage of pathogenic organisms associated with recurrent otitis media, which medicament is adapted for nasal administration, in particular, focussed delivery to the nasopharynx.

15 To lessen the risk of encouraging the development of mupirocin resistant organisms, it is preferred to administer of mupirocin or a pharmaceutically acceptable salt or ester thereof on an intermittent, rather than a continual, basis.

20 Accordingly, in a further aspect, the present invention provides the use of mupirocin or a pharmaceutically acceptable salt or ester thereof (hereinafter referred to as drug substance) in the manufacture of a medicament adapted for administration to the nasopharynx and which is administered to a patient in need thereof on an intermittent basis.

25 In a suitable intermittent treatment regimen, drug substance (mupirocin or a pharmaceutically acceptable ester or salt) is administered on a daily basis, for a small number of days, for instance from 2 to 10, suitably 3 to 8, more suitably about 5 days, the administration then being repeated after an interval, for instance, on a monthly basis over

30 a period of months, for instance up to six months.

Less preferably, the drug substance may be administered on a continuing, daily basis, over a prolonged period, for instance several months.

35 Suitably drug substance is administered twice a day. Suitably, drug substance is administered during the winter months when bacterial infections such as recurrent otitis media and recurrent sinusitis tend to be more prevalent.

Suitably, drug substance is administered at a dosage of from 1 to 10mg, preferably from 3 to 8, typically about 5mg, in each nostril, twice a day.

5 The drug substance is administered to the nasopharynx, in particular the anterior nasopharynx.

Suitable pharmaceutically acceptable salts of mupirocin are well known in the art and include alkali metal salts such as sodium and lithium and alkaline earth metal salts such 10 as calcium, of which the calcium salt is preferred, in particular the crystalline dihydrate form thereof described in EP 0 167 856-A (Beecham Group), as well as other metal salts, for instance silver and aluminium salts and ammonium substituted ammonium salts. The salts may be anhydrous or may be in the form of pharmaceutically acceptable solvates, for 15 instance alcoholates and, especially, hydrates. Preferred salts include the calcium, silver and lithium salts, in particular the calcium salt. In the case of the calcium salt of mupirocin, the crystalline salt, preferably the crystalline hydrated calcium salt, more 20 preferably the crystalline dihydrate salt, is used. Preferably, the crystalline hydrated calcium salt is used.

20 Accordingly, in a further aspect, the present invention provides for the use of the crystalline calcium dihydrate salt of mupirocin in the manufacture of a medicament for the prophylactic treatment of conditions associated with bacterial colonisation of the nasopharynx.

25 Suitable pharmaceutically acceptable esters are well known in the art and include lower alkyl esters, especially the methyl and ethyl esters.

Suitably, the drug substance is present in medicaments for use in the present invention in a between 0.01 and 10%, preferably 0.1 and 5%, more preferably 1 and 5%. Suitable 30 amounts include 2% and 4% by weight of the medicament. It is preferred to avoid low level dosages of drug substance as this might increase the risk of the development of mupirocin resistant bacteria.

35 Accordingly, in a further aspect, the present invention provides for the use of mupirocin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament for the prophylactic treatment of bacterial infection, characterised in that the medicament

is administered to the nasopharynx and comprises from 0.5 to 5% by weight of mupirocin or a pharmaceutically acceptable salt or ester.

Preferred compositions for administration include those adapted for focussed delivery to, 5 and residence within, the nasopharynx. The term 'focussed delivery' is used to mean that the composition is delivered to the nasopharynx, rather than remaining within the nares. The term 'residence' within the nasopharynx is used to mean that the composition once delivered remains within the nasopharynx over a course of several hours, rather than being washed away more or less immediately. These two aspects may be conveniently 10 studied by γ (gamma) ray scintigraphy. Suitable such compositions include sprays and creams.

Accordingly, in a further aspect, the present invention provides for a sprayable pharmaceutical formulation comprising:

15 (a) an amphiphilic agent that increases in viscosity on contact with water;
(b) a non-aqueous diluent for the amphiphilic agent,
(c) powdered drug substance in suspension.

Amphiphilic agents are substances containing both hydrophilic and lipophilic groups. In 20 liquid form, these agents are generally capable of spontaneous self-association in the presence of water, with a consequent increase in viscosity. This self-association results in a change in properties ranging from the formation of viscous liquids to semi-rigid gels. This behaviour has been characterised as due to the formation of long range order in the liquid system giving several distinct phases which have been called "liquid crystalline 25 phases".

Materials known to exhibit such properties and which are suitable for use in a pharmaceutical formulation include mono-glycerides such as mono-olein and mono-linolein, phospholipids such as phosphatidyl cholines, and galactolipids such as galactoyl-30 diglycerides.

Typically the monoglycerides are long-chain fatty acid monoglycerides, optionally comprising up to 10% (w/w) of a long-chain fatty acid diglyceride and/or a small amount by weight of a free long-chain fatty acid. The mono- and di-glycerides may each include 35 blends of different long-chain fatty acid mono- and di-glycerides. Suitable long-chain fatty acid monoglycerides include glycerol monooleate, glycerol monopalmitate and glycerol monostearate. Suitable commercially available examples of such include the

products available under the trade names MYVEROL, such as MYVEROL 18-99, MYVATEX, MYVAPLEX, and GMORPHIC 80 respectively, from Eastman Kodak Chemicals, Rochester, New York. A further useful long-chain fatty acid monoglyceride-containing product is ARLACEL 186 (available from ICI Americas Inc.) which includes, 5 in addition to glycerol monooleate, propylene glycol (10%). The main fatty acids of MYVEROL 18-99 are oleic acid (61%), linoleic acid (21%), linolenic acid (9%) and palmitic acid (4%). Suitably in such long-chain monoglycerides, the major fatty acid component is a C₁₈-saturated, monounsaturated or polyunsaturated fatty acid, preferably a C₁₈-monounsaturated or polyunsaturated fatty acid. Suitably the monoglyceride will 10 have an HLB value in the range of about 2.5 to 6. The HLB value of the product MYVEROL 18-99 is 3.7.

In the present invention the amphiphilic substance is preferably glyceryl mono-oleate (mono-olein). As indicated above, in its commercially available form, glyceryl mono-oleate is a material which is predominantly glyceryl mono-oleate but also contains minor 15 amounts of related mono and di-glycerides. Accordingly, the amount that is effective in a particular spray formulation will vary dependent on the level of glyceryl mono-oleate in the commercial material used.

20 To obtain a sprayable formulation, the amphiphilic substance is combined with a liquid diluent. The diluent is selected on the basis of compatibility e.g. producing a stable blend with the amphiphilic agent, and the ability to achieve a sprayable blend without excessive dilution that will reduce the self-association on contact with water and detract from the desired viscosity increase. Typically, a diluent is a pharmaceutically acceptable oil, most 25 preferably a fatty acid triglyceride, typically vegetable (i.e. plant derived) oil, since mineral oils such as paraffin oil have been implicated in undesirable side effects when inhaled. Suitable vegetable oils include coconut oil, sesame oil and soya bean oil. In this invention, the preferred diluent is a vegetable oil, most preferably coconut oil, that has been fractionated so that it is predominantly medium chain length triglycerides. 30 Typically the proportion of amphiphilic agent to oil is from 2:1 to 1:4, preferably 1:1 to 1:2. Ideally, the amount of diluent is adjusted so that the formulation is of a viscosity that is suitable for spray delivery at 20°C or above.

Suitable medium-chain fatty acid triglycerides for use in the present invention may be of 35 natural, semi-synthetic or synthetic origin and may include blends of different medium chain fatty acid triglycerides. The term "medium-chain fatty acid" as used herein refers to a fatty acid having from 6 to 12, preferably 8 to 10 carbon atoms which may be branched or unbranched, preferably unbranched and which may be optionally substituted. Certain

neutral plant oils, such as fractionated coconut oils, provide convenient sources of medium-chain fatty acid triglycerides. The triglyceride suitably comprises from 50 to 100% (w/w) of caprylic (C₈) acid and from 0 to 50% (w/w) of capric (C₁₀) acid triglycerides. Suitable examples include those available under the trade names

- 5 MYRITOL; CAPTEX (Karlshams Lipid Specialties, Columbus OH), for instance CAPTEX 355, CAPTEX 300, CAPTEX 350, CAPTEX 850 and CAPTEX 8000; MIGLYOL (BASF), for instance the grades MIGLYOL 810, MIGLYOL 812 AND MIGLYOL 818 (which also comprises a linoleic acid triglyceride) and MAZOL 1400 (Mazer Chemical, Guernee, II). The fatty acid content of representative products is:
- 10 CAPTEX 355™ - CAPROIC ACID (2%), CAPRYLIC ACID (55%) and capric acid (42%); CAPTEX 8000 - at least 98% caprylic acid, MYGOL 810 - caproic acid (2%), caprylic acid (65-75%), capric acid (25-35%) and MIGLYOL 812 - caproic acid (3%), caprylic acid (50-65%), capric acid (30-45%) and lauric acid (5%) (manufacturer's data).

- 15 In the present formulations, the drug substance is used at between 2 and 8%, suitably between 3 and 5%, typically about 4%, by weight of the formulation. It is preferred to use a relatively high dosage level, to reduce the risk of the development of bacterial resistance. Also, to avoid excessive delivery volumes which will be uncomfortable in nasal administration, the drug substance is preferably present at a relatively high loading
- 20 compared to other topical administration formulations.

Suitably, the drug substance is micronised calcium mupirocin dihydrate. Suitably the drug substance has a particle size less than 100 µm, preferably less than 10 µm.

- 25 The sprayable formulations of this invention are especially suitable for delivery to and residence within the nasopharynx, because in the humid environment of the nasal passages they increase in viscosity by contact with water, and so are better able to resist wash-out when in contact with nasal surfaces.
- 30 Other sprayable formulations for use in the present invention include solutions of drug substance, preferably mupirocin, in aqueous polyethylene glycol. Such sprays may be conveniently prepared on an extemporaneous basis by diluting a pharmaceutical composition comprising drug substance, preferably mupirocin, in polyethylene glycol, or a derivative thereof, with an aqueous solution, for instance water, or, preferably, a saline
- 35 solution. Suitable such compositions are described in EP 0 095 897-A2 (Beecham Group). Suitably, the pharmaceutical composition comprises from 0.01 to 50% mupirocin in polyethylene glycol, suitably a mixture of polyethylene glycol 400 and polyethylene glycol 4000. In a representative example, the pharmaceutical composition

comprises 2% mupirocin in mixture of polyethylene glycol 400 (59%) and polyethylene glycol 4000 (39%). Suitably, the mupirocin containing composition is diluted with aqueous solution in a ratio of from 1:1 to 1:20, more suitably 1:5 to 1:15, preferably about 1:9 to 1:10. Suitably, in the nasal spray, drug substance is incorporated at between 0.01
5 and 1%, suitably 0.1 to 0.5% by weight of the composition. Suitably such aqueous compositions comprising mupirocin are stored at about 5°C and are not stored for prolonged periods, as mupirocin is known to be susceptible to degradation on prolonged exposure to an aqueous environment.

10 The mupirocin formulation and aqueous solution for the extemporaneous preparation of the nasal spray may be conveniently provided in a kit. Accordingly, in a further aspect, the present invention provides for a kit comprising, in a first part, a pharmaceutical formulation comprising drug substance, preferably mupirocin, in polyethylene glycol, or a derivative thereof, as hereinbefore described, and, in a second part, an aqueous solution.
15 The first and second parts may be supplied in separate containers or in single container with the two parts separated by a barrier which is removed or broken prior to use. Suitably the kit includes a container adapted for use as a nasal spray device.

Further suitable formulations include creams adapted for focussed delivery to the
20 nasopharynx. Such formulations with appropriate viscosity characteristics may be provided in containers adapted for nasal administration, for instance having an extended nozzle.

According, in a further aspect, the present invention provides a pharmaceutical
25 formulation consisting essentially of
2 - 8 % by wt. of drug substance;
50 - 70 % by wt. of a fatty acid triglyceride;
2 - 6 % by wt. of a polyoxyethylene ether or ester surfactant;
2 - 4 % by wt. of a fatty alcohol or ester;
30 30 - 40 % by wt. of water; and
up to 2 % by wt. of conventional additive such as preservatives and flavourings.

For nasal administration the issue of patient comfort is important in compliance with the intended treatment regime. The formulation of this invention provides a low viscosity
35 cream that is easy to administer and which readily changes in consistency and softens in the temperature conditions of the nose. Accordingly when inserted into the upper regions of the nose it can be transported deeper into the nasal passages by natural processes. The

composition is intended to be in the form of an oil-in-water cream emulsion. In view of the large triglyceride content which provides the desired consistency for nasal administration, and the relatively low content of surfactant, the amounts of the components within the above ranges must be selected for individual components by 5 routine trials to ensure that an oil-in-water emulsion is obtained.

The fatty acid triglycerides are typically vegetable (i.e. plant-derived) oils, such as coconut oil, sesame oil or soya bean oil. An especially suitable vegetable oil is one that has to been fractionated so that it is predominantly medium chain length triglycerides.

10 Suitable medium-chain fatty acid triglycerides for use in the present invention may be of natural, semi-synthetic or synthetic origin and may include blends of different medium chain fatty acid triglycerides. The term "medium-chain fatty acid" as used herein refers to a fatty acid having from 6 to 12, preferably 8 to 10 carbon atoms which may be branched 15 or unbranched, preferably unbranched and which may be optionally substituted. Certain neutral plant oils, such as fractionated coconut oils, provide convenient sources of medium-chain fatty acid triglycerides. The triglyceride suitably comprises from 50 to 100% (w/w) of caprylic (C₈) acid and from 0 to 50% (w/w) of capric (C₁₀) acid triglycerides. Suitable examples include those available under the trade names 20 MYRITOL; CAPTEX (Karlshams Lipid Specialties, Columbus OH), for instance CAPTEX 355, CAPTEX 300, CAPTEX 350, CAPTEX 850 and CAPTEX 8000; MIGLYOL (BASF), for instance the grades MIGLYOL 810, MIGLYOL 812 AND MIGLYOL 818 (which also comprises a linoleic acid triglyceride) and MAZOL 1400 (Mazer Chemical, Guernee, II). The fatty acid content of representative products is: 25 CAPTEX 355TM - CAPROIC ACID (2%), CAPRYLIC ACID (55%) and capric acid (42%); CAPTEX 8000 - at least 98% caprylic acid, MYGOL 810 - caproic acid (2%), caprylic acid (65-75%), capric acid (25-35%) and MIGLYOL 812 - caproic acid (3%), caprylic acid (50-65%), capric acid (30-45%) and lauric acid (5%) (manufacturer's data).

30 The polyoxyethylene ether or ester used in this invention is one which will function as a non-ionic surfactant. Especially suitable materials include polyoxyethylene glycol monocetyl ethers, such as Cetomacrogol 1000. Other suitable non-ionic surfactants include:

35 (a) polyoxyethylene fatty acid esters, for example polyoxyethylene stearic acid esters of the type available under the trade name MYRJ (ICI Americas, Inc.), for instance the product MYRJ 52 (a polyoxyethylene 40 stearate);

(b) polyoxyethylene-sorbitan fatty acid esters (polysorbates), for example the mono- and tri-lauryl, palmityl, stearyl and oleyl esters, for instance the polyoxyethylene sorbitan

monooleates available under the trade name of TWEEN (ICI Americas Inc.), such as TWEEN 20, 21, 40, 60, 61, 65, 80, 81 and 85, of which class TWEEN 80 is especially preferred;

(c) polyoxyethylene glycol long-chain alkyl ethers, such as polyoxyethylated glycol

5 lauryl ether; and

(d) polyoxyethylene glycol long-chain alkyl esters, such as PEG-monostearate.

For use herein, the surfactant preferably has an HLB value in the range of 13 to 20.

10 As fatty alcohol or ester there may be used any of such materials conventionally used in pharmaceutical or veterinary formulations such as stearyl alcohol, cetyl alcohol, cetyl stearyl alcohol, myristyl alcohol and glycerin monostearate. Preferably, cetostearyl alcohol is used, or a mixture of stearyl alcohol and cetyl alcohol.

15 A particularly preferred vehicle formulation comprises fractionated coconut oil (typically about 55 to 60, especially about 57, parts by weight); polyoxyethylene glycol monocetyl ether (typically about 2 to 4, especially about 3, parts by weight); cetostearyl alcohol (typically about 2 to 4, especially about 3, parts by weight); with water for emulsification, and also preservatives, and flavourings if desired.

20 Typical preservatives include benzyl alcohol and phenoxyethanol.

Suitably, the drug substance is the calcium salt of mupirocin, in particular the calcium dihydrate salt. This is preferably present as a finely divided powder. This may be 25 achieved by milling, and most suitably by micronising (fluid energy milling) so that the medicament has a particle size less than 100 µm, preferably less than 10 µm.

In the formulation of this invention the drug substance is used at between 2 and 8%, 30 suitably between 3 and 5%, typically about 4%, by weight of the formulation. It is preferred to use a relatively high dosage level, to reduce the risk of the development of bacterial resistance. Also, to avoid excessive delivery volumes which will be uncomfortable in nasal administration, the drug substance is preferably present at a relatively high loading compared to other topical administration formulations.

35 The formulation may typically be administered into the nasal passages by a pump, such as an air lift pump. This may be adapted for nasal administration by addition of a modified nozzle.

Formulations of this invention may be produced by conventional pharmaceutical techniques. Thus, for example, the components of the carrier may be blended by mixing together at an elevated temperature until an emulsion has formed. The mixture may then be cooled to room temperature, and, after the addition of any further optional ingredients, 5 stirred to ensure adequate dispersion. The antibiotic may be added during hot preparation of the base, or may be added with additional ingredients after cooling of the base. If necessary the composition may be provided in sterile condition.

Optional ingredients that may be added if desired include colourings and flavourings.

10

The skilled person will readily appreciate that in the novel spray and cream formulations hereinbefore described, mupirocin may be replaced by another antibiotic agent. The present invention encompasses all such formulations.

15 The invention is illustrated by the following Examples.

Example 1 - Spray Formulation

A carrier for a nasal spray formulation was prepared by forming a blend of 67% w/w fractionated coconut oil (medium chain length)* and 33% w/w of glyceryl mono-oleate **. To this blend was added 0.2% w/w of powdered lemon juice flavour, followed by 4% w/w of micronized calcium Mupirocin.

The resultant formulation has a viscosity which is sprayable at 20°C or above. When sprayed into the nose of a patient, the liquid coats the nasal passages and contact with moisture inside the nose (from the mucous membranes, and the humid environment generally) causes the carrier to thicken. This prolongs the residence time of the sprayed formulation on the nasal surfaces. A spray volume of about 125 µl contains approximately 5 mg Mupirocin.

*Commercial product Miglyol, obtainable from Hüls

** Commercial product Myverol 18-99, obtainable from Eastman

Example 2 - cream

An oil-in-water emulsion cream was prepared from the following:

| | | |
|----|--|-------|
| 20 | Calcium Mupirocin | 4% |
| | Fractionated Coconut Oil* | 57.3% |
| | Polyoxyethylene glycol monocetyl ether | 3% |
| | Cetostearyl alcohol | 3% |
| | Benzyl Alcohol | 1% |
| 25 | Phenoxy ethanol | 0.5% |
| | Water | 35% |
| | Lemon juice flavour (powdered) | 0.2% |

*Commercial product Miglyol, obtainable from BASF

Claims

1. The use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for the prophylactic treatment of bacterial infection associated with colonisation of the nasopharynx by pathogenic organisms, and in which the medicament is adapted for administration to, and residence within, the nasopharynx; excluding the use of a 0.2% saline solution of mupirocin for treating recurrent sinusitis, administered at a dosage of less than 1mg a day, twice daily on a continuing basis.
- 5 2. A use as claimed in claim 1 in which the bacterial infection is recurrent otitis media or recurrent sinusitis.
- 10 3. The use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament adapted for administration to the nasopharynx for the prophylactic treatment of recurrent otitis media.
- 15 4. The use of mupirocin or a pharmaceutically acceptable ester or salt thereof in the manufacture of a medicament for reducing or eliminating the nasal carriage of pathogenic organisms associated with recurrent otitis media, which medicament is adapted for nasal administration.
- 20 5. The use of mupirocin or a pharmaceutically acceptable salt or ester thereof in the manufacture of a medicament which is administered to the nasopharynx of a patient in need thereof on an intermittent basis.
- 25 6. A use as claimed in claim 5 in which the medicament is administered on a daily basis, for 2 to 10 days, and then repeated on a monthly basis.
- 30 7. A use as claimed in any one of the preceding claims in which mupirocin or a pharmaceutically acceptable ester or salt thereof is administered at a dosage of from 1 to 10mg in each nostril, twice a day.
- 35 8. A sprayable formulation suitable for nasal delivery of a medicament comprising:
 - (a) an amphiphilic agent that increases in viscosity on contact with water;
 - (b) a non-aqueous diluent for the amphiphilic agent, and
 - (c) mupirocin or a pharmaceutically acceptable ester or salt thereof in suspension.

9. A formulation as claimed in claim 8 in which the amphiphilic agent is selected from mono-glycerides, phospholipids and galactolipids.
10. A formulation as claimed in claim 9 in which the amphiphilic agent is glyceryl
5 mono-oleate (mono-olein).
11. A formulation as claimed in any one of claims 8 to 10 in which the diluent is a pharmaceutically acceptable oil.
- 10 12. A formulation as claimed in claim 11 in which the diluent is a fatty acid triglyceride oil.
13. A formulation as claimed in claim 12 in which the fatty acid triglyceride oil is coconut oil, sesame oil or soya bean oil.
- 15 14. A formulation as claimed in claim 12 or 13 in which the fatty acid triglyceride has been fractionated so that it is predominantly medium chain length triglycerides.
- 20 15. A formulation according to any one of claims 11 to 14 in which the proportion of amphiphilic agent to oil is from 2:1 to 1:4.
16. A pharmaceutical formulation consisting essentially of
2 - 8% by wt. of mupirocin or a pharmaceutically acceptable ester or salt thereof;
50 - 70 % by wt. of a fatty acid triglyceride;
25 2 - 6 % by wt. of a polyoxyethylene ether or ester surfactant;
2 - 4 % by wt. of a fatty alcohol or ester;
30 - 40 % by wt. of water; and
up to 2 % by wt. of conventional additives.
- 30 17. A formulation as claimed in claim 16 in which the fatty acid triglyceride is a vegetable oil fractionated to medium chain lengths.
18. A formulation as claimed in claim 16 in which the fatty acid triglyceride is fractionated coconut oil.
- 35 19. A formulation as claimed in any one of claims 15 to 18 in which the polyoxyethylene ether is Cetomacrogol 1000.

20. A formulation as claimed in any one of claims 15 to 19 in which the fatty alcohol is cetostearyl alcohol or a mixture of cetyl and stearyl alcohols.
21. A formulation as claimed in any one of claims 15 to 20 which is an oil in water emulsion containing about 57 % by weight of fractionated coconut oil, about 3 % by weight of Cetomacrogol 1000 and about 3 % by weight of cetostearyl alcohol.
5
22. A formulation as claimed in any one of claims 8 to 21 which mupirocin or a pharmaceutically acceptable ester or salt thereof comprises from 1 to 10% by weight of the formulation.
10
23. A formulation as claimed in claim 22 which comprises the calcium dihydrate salt of mupirocin.
- 15 24. A kit comprising, in a first part, a pharmaceutical composition comprising mupirocin in polyethylene glycol vehicle, and, in a second part, an aqueous solution.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02664

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| X, Y | <p>BOYCE J. M. ET AL.: "Spread of methicillin-resistant staphylococcus aureus in a hospital after exposure to a health care worker with chronic sinusitis" CLIN. INFECT. DIS., vol. 17, no. 3, September 1993, USA, pages 496-504, XP002052565 see page 501, left-hand column, line 3 - line 44</p> <p>---</p> <p>-/-</p> | 1-24 |

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents .

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

1

| | |
|---|--|
| Date of the actual completion of the international search | Date of mailing of the international search report |
| 19 January 1998 | 06.02.98 |
| Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl Fax: (+31-70) 340-3016 | Authorized officer Economou, D |

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 97/02664

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|----------|---|-----------------------|
| X,Y | EP 0 095 897 A (BEECHAM GROUP PLC.) 7 December 1983 cited in the application see page 1, line 1 - page 3, line 13 see page 3, last paragraph see page 4, line 1 - page 5, line 13 see page 5, line 14 - line 28 see page 6, line 6 - line 12 see examples 1-5 see claims 1-10 --- | 8,16,19, 22-24 |
| X,Y | EP 0 251 434 A (BEECHAM GROUP PLC.) 7 January 1988 see page 3, line 7 - line 17 see page 3, line 44 - page 4, line 7 see page 4, line 15 - line 22 see page 4, line 41 - line 53 see page 5, line 1 - line 31 see page 6, line 1 - line 17 see examples 6-9 --- | 8-24 |
| Y | EP 0 167 856 A (BEECHAM GROUP OLC.) 15 January 1986 cited in the application see claim 2 --- | 23 |
| X,Y | WO 95 10999 A (SMITHKLINE BEECHAM CO) 27 April 1995 cited in the application see page 1, line 30 - page 3, line 10 see examples 1-3 ----- | 1-24 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02664

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|--|--|
| EP 0095897 A | 07-12-83 | AU 1488583 A CA 1196284 A DE 3378523 A HK 21991 A JP 1683981 C JP 3048886 B JP 58219108 A US 4524075 A | 01-12-83 05-11-85 29-12-88 28-03-91 31-07-92 25-07-91 20-12-83 18-06-85 |
| EP 0251434 A | 07-01-88 | AU 600264 B AU 7132987 A DE 3780091 A DK 186087 A IE 59628 B JP 63008331 A US 4790989 A | 09-08-90 07-01-88 06-08-92 27-12-87 09-03-94 14-01-88 13-12-88 |
| EP 0167856 A | 15-01-86 | AU 577595 B AU 4373485 A CA 1242437 A DK 275585 A,B, IE 58118 B JP 2003630 C JP 7023373 B JP 61017583 A SI 8511013 A US 5436266 A US 4916155 A US 5569672 A US 5191093 A | 29-09-88 02-01-86 27-09-88 20-12-85 14-07-93 20-12-95 15-03-95 25-01-86 31-08-96 25-07-95 10-04-90 29-10-96 02-03-93 |
| WO 9510999 A | 27-04-95 | AU 8084794 A BG 100501 A BR 9407840 A CA 2174658 A CN 1135715 A CZ 9601120 A EP 0727979 A FI 961720 A HU 74510 A | 08-05-95 31-12-96 13-05-97 27-04-95 13-11-96 17-07-96 28-08-96 19-04-96 28-01-97 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/GB 97/02664

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|--|------------------|-------------------------|------------------|
| WO 9510999 A | | JP 9506865 T | 08-07-97 |
| | | NO 961588 A | 19-04-96 |
| | | NZ 275282 A | 28-10-96 |
| | | PL 314038 A | 05-08-96 |
| | | SK 49596 A | 05-02-97 |
| | | ZA 9408231 A | 25-07-95 |

THIS PAGE BLANK (USPTO)